- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00847301
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Observational Cohort Study to Evaluate Safety and Efficacy of Pradaxa (Dabigatran Etexilate) in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne
- 1160.84.04903 Boehringer Ingelheim Investigational Site
-
Erlangen, Allemagne
- 1160.84.04947 Boehringer Ingelheim Investigational Site
-
Gelnhausen, Allemagne
- 1160.84.4922 Boehringer Ingelheim Investigational Site
-
Hachenburg, Allemagne
- 1160.84.04927 Boehringer Ingelheim Investigational Site
-
Koblenz, Allemagne
- 1160.84.04929 Boehringer Ingelheim Investigational Site
-
Marburg, Allemagne
- 1160.84.04902 Boehringer Ingelheim Investigational Site
-
München, Allemagne
- 1160.84.04946 Boehringer Ingelheim Investigational Site
-
Olsberg, Allemagne
- 1160.84.04913 Boehringer Ingelheim Investigational Site
-
Sylt, Allemagne
- 1160.84.04914 Boehringer Ingelheim Investigational Site
-
Wismar, Allemagne
- 1160.84.04938 Boehringer Ingelheim Investigational Site
-
Würzburg, Allemagne
- 1160.84.04948 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Badalona (Barcelona), Espagne
- 1160.84.3409 Boehringer Ingelheim Investigational Site
-
Barcelona, Espagne
- 1160.84.3410 Boehringer Ingelheim Investigational Site
-
Madrid, Espagne
- 1160.84.3403 Boehringer Ingelheim Investigational Site
-
Malaga, Espagne
- 1160.84.3405 Boehringer Ingelheim Investigational Site
-
Pamplona, Espagne
- 1160.84.3404 Boehringer Ingelheim Investigational Site
-
Pozuelo de Alarcón - Madrid, Espagne
- 1160.84.3412 Boehringer Ingelheim Investigational Site
-
Valencia, Espagne
- 1160.84.3401 Boehringer Ingelheim Investigational Site
-
Zaragoza, Espagne
- 1160.84.3402 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Angers, France
- 1160.84.3311 Boehringer Ingelheim Investigational Site
-
Bordeaux, France
- 1160.84.3334 Boehringer Ingelheim Investigational Site
-
Caen Cedex 5, France
- 1160.84.3303 Boehringer Ingelheim Investigational Site
-
Clermont-Ferrand cedex 1, France
- 1160.84.3314 Boehringer Ingelheim Investigational Site
-
Creteil, France
- 1160.84.3320 Boehringer Ingelheim Investigational Site
-
DIJON Cédex, France
- 1160.84.3307 Boehringer Ingelheim Investigational Site
-
Illkirch, France
- 1160.84.3310 Boehringer Ingelheim Investigational Site
-
Le Havre, France
- 1160.84.3335 Boehringer Ingelheim Investigational Site
-
Les Lilas, France
- 1160.84.3326 Boehringer Ingelheim Investigational Site
-
Lyon, France
- 1160.84.3312 Boehringer Ingelheim Investigational Site
-
Marseille, France
- 1160.84.3305 Boehringer Ingelheim Investigational Site
-
Nantes Cédex 2, France
- 1160.84.3323 Boehringer Ingelheim Investigational Site
-
Paris, France
- 1160.84.3302 Boehringer Ingelheim Investigational Site
-
Paris, France
- 1160.84.3306 Boehringer Ingelheim Investigational Site
-
Pierre Bénite cedex, France
- 1160.84.3313 Boehringer Ingelheim Investigational Site
-
Poitiers Cédex, France
- 1160.84.3324 Boehringer Ingelheim Investigational Site
-
Saint Etienne Cédex 2, France
- 1160.84.3322 Boehringer Ingelheim Investigational Site
-
Saint Saulve, France
- 1160.84.3319 Boehringer Ingelheim Investigational Site
-
Toulouse Cédex 9, France
- 1160.84.3316 Boehringer Ingelheim Investigational Site
-
Vannes Cédex, France
- 1160.84.3332 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Latina, Italie
- 1160.84.03908 Boehringer Ingelheim Investigational Site
-
Milano, Italie
- 1160.84.03902 Boehringer Ingelheim Investigational Site
-
Monza, Italie
- 1160.84.03904 Boehringer Ingelheim Investigational Site
-
Udine, Italie
- 1160.84.03909 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Wien, L'Autriche
- 1160.84.4301 Boehringer Ingelheim Investigational Site
-
Wien, L'Autriche
- 1160.84.4310 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basildon, Royaume-Uni
- 1160.84.04405 Boehringer Ingelheim Investigational Site
-
Bedford, Royaume-Uni
- 1160.84.04408 Boehringer Ingelheim Investigational Site
-
Luton, Royaume-Uni
- 1160.84.04403 Boehringer Ingelheim Investigational Site
-
Wigan, Royaume-Uni
- 1160.84.04401 Boehringer Ingelheim Investigational Site
-
Yeovil, Royaume-Uni
- 1160.84.04407 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kungälv, Suède
- 1160.84.4603 Boehringer Ingelheim Investigational Site
-
Motala, Suède
- 1160.84.4601 Boehringer Ingelheim Investigational Site
-
Sollefteå, Suède
- 1160.84.4604 Boehringer Ingelheim Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion criteria:
Patients of 18 years of age or above with moderate renal impairment (creatinine clearance 30-50 ml/min) undergoing elective total hip replacement surgery who consent in writing to their participation in this observational study
Exclusion criteria:
All patients who should not be treated with Pradaxa 150 mg according to the European Summary of Product Characteristics (SPC):
severe renal impairment (creatinine clearance < 30 ml/min); elevated liver enzymes > 2 upper limit of normal (ULN); Hepatic impairment or liver disease expected to have any impact on survival, anaesthesia with post-operative indwelling epidural catheters, hypersensitivity to dabigatran etexilate or to any of the excipients, active clinically significant bleeding, organic lesion at risk of bleeding, spontaneous or pharmacological impairment of haemostasis, concomitant treatment with quinidine, protehetic heart valve requiring anticoagulant treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Renal Impairment
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percentage of Patients With Major Bleeding Events (MBE)
Délai: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Major bleeding events were defined according to the modified McMaster criteria, and were classified by the investigator as Major bleeding event or Any bleeding event.
The criteria for MBE's were: fatal; clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected; clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected; symptomatic retroperitoneal, intracranial, intraocular or intraspinal; requiring treatment cessation; leading to re-operation
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Symptomatic Venous Thromboembolic Events (sVTE) and All Cause Mortality
Délai: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
The co-primary efficacy variable sVTE was defined as the composite of documented symptomatic proximal and distal deep vein thrombosis (DVT) and documented symptomatic non-fatal pulmonary embolism (PE) and All Cause Mortality.
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Documented Symptomatic Proximal DVT, Documented Symptomatic Distal DVT, Documented Symptomatic Nonfatal Pulmonary Embolism and All-cause Mortality
Délai: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of participant with documented symptomatic proximal DVT (deep vein thrombosis), documented symptomatic distal DVT, documented symptomatic nonfatal pulmonary embolism and all-cause mortality
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Major Extra-surgical Site Bleedings
Délai: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Major Extra-surgical Site Bleedings
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Volume of Wound Drainage (Post-operative)
Délai: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Volume of Wound Drainage after surgery
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1160.84
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .